QT Imaging Completes 1st In Class and 1st In Human Study: Quantitative Transmission Ultrasound Research Shows Better Performance than Mammography

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

January 5, 2021

QT Imaging, a developer of the FDA-cleared QTscan®, has completed a first-in-class and first-in-human study of transmission ultrasound as a new imaging technology for breast health screening.

The recently published study in Academic Radiology found that, compared to full-field digital mammography (FFDM), transmission ultrasound showed increased sensitivity, increased specificity, and lower recall rates.

Figure 4. Overall performance of the radiologists as measured in terms of recall rates for QT and FFDM. The horizontal axis marks the difference between the recall rates of QT and FFDM. A lower than zero value indicates QT shows improvement over FFDM; a greater than zero value indicates FFDM shows improvement over QT. Square (▪) markers correspond to RRRC results; circle (•) markers correspond to RRFC results.

 

 

 

 

 

 

 

 

Figure 2. (A) Representative speed-of-sound image (right) and the corresponding whole breast H&E section (left) showing correlation of glandular and ductal histology with the speed-of-sound image

 

 

 

 

 

 

 

 

 

 

QT Imaging CEO and Chief Medical Officer Dr. John Klock advises, “This research represents an important milestone because it’s the first time a novel technology was compared to the standard of care in breast imaging in a primary breast cancer screening setting. While we are very encouraged by a 4% higher sensitivity, meaning the new modality can detect more lesions, the results of 16% higher specificity for transmission ultrasound is extremely promising. To have the ability to know if a lesion is problematic or not can be a game-changer, resulting in reduced callbacks, reduced biopsies, less anxiety for women, and perhaps even reduced healthcare costs.”

Transmission ultrasound is free of radiation, compression, and contrast injections, which makes it a safe, comfortable imaging experience for women of all ages. For younger women at high-risk for breast cancer, who do not qualify for x-ray mammography, it may provide a safer option that would allow them to have breast screening earlier and more often. QT Imaging will use this study, and additional ones, to secure FDA clearance for screening younger at-risk women under its FDA Breakthrough Device Designation.

While the published retrospective study shows that the inherently 3D nature of transmission ultrasound resulting in high resolution and high contrast-to-noise ratio makes it effective in evaluating breast tissue, a prospective study comparing true 3D transmission ultrasound to 3D breast tomosynthesis is warranted and will be published in the future. Based on learnings thus far, QT Imaging believes it is likely that transmission ultrasound will maintain its advantage in improved specificity and reduced callback rates.

Digital mammography has reduced mortality in the last couple of decades, but the industry now understands that interpreting mammographic images can be challenging in some scenarios, especially for women with extremely dense breasts. Advancements in the field will be welcomed by healthcare professionals, imaging experts, and the women they serve.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.